Growth factor receptors as therapeutic targets: Strategies to inhibit the insulin-like growth factor I receptor

Oncogene

Volumn 22, Issue 43, 2003, Pages 6589-6597

  Surmacz, Eva ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Anti cancer drugs; Antibodies; Antisense; Dominant negative mutants; Insulin like growth factor receptor; Triple helix; Tyrosine kinase inhibitors

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; BCR ABL KINASE; CETUXIMAB; COMPLEMENTARY RNA; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEFITINIB; GROWTH FACTOR RECEPTOR; GROWTH FACTOR RECEPTOR ANTIBODY; GROWTH FACTOR RECEPTOR BLOCKER; IMATINIB; LIGAND; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 391; MONOCLONAL ANTIBODY ALPHA IR3; PHOSPHOTRANSFERASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PODOPHYLLOTOXIN DERIVATIVE; PROTEIN ERB2; PROTEIN TYROSINE KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; RECEPTOR ANTIBODY; RECEPTOR BLOCKING AGENT; RNA; SMALL INHIBITORY RNA; SOMATOMEDIN C RECEPTOR; STEM CELL FACTOR RECEPTOR; SYNTHETIC PEPTIDE; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; WO 02 092599; WO 02 102804;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER; CARCINOGENICITY; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; HUMAN; MALIGNANT TRANSFORMATION; METASTASIS; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TRIPLE HELIX;

EID: 0242624594     PISSN: 09509232     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.onc.1206772     Document Type: Review

References (110)

1. Adachi Y, Lee CT, Coffee K, Yamagata N, Ohm JE, Park KH, Dikov MM, Nadaf SR, Arteaga CL and Carbone DP. (2002). Gastroenterology, 123, 1191-1204.
2. Adams TE, Epa VC, Garrett TP and Ward CW. (2000). Cell. Mol. Life Sci., 57, 1050-1093.
3. Andrews DW, Resnicoff M, Flanders AE, Kenyon L, Curtis M, Merli G, Baserga R, Iliakis G and Aiken RD. (2001). J. Clin. Oncol. 19, 2189-2200.
4. Arteaga CL. (1992). Breast Cancer Res. Treat., 22, 101-116.
5. Arteaga CL. (2003). Exp. Cell Res., 284, 122-130.
6. Arteaga CL, Kitten LJ, Coronado EB, Jacobs S, Kull Jr FC, Allred DC and Osborne CK. (1989). J. Clin. Invest., 84, 1418-1423.
7. Bartucci M, Morelli C, Mauro L, Ando' S and Surmacz E. (2001). Cancer Res., 61, 6747-6754.
8. Baserga R. (1994). Cell, 79, 927-930.
9. Baserga R. (1995). Cancer Res., 55, 249-252.
10. Baserga R. (1996). Trends Biotechnol., 14, 150-152.
11. Baserga R. (1997). Exp. Cell Res., 236, 1-3.
12. Baserga R. (1998). Hormones and Growth Factors in Development and Neoplasia Dickson R, Salomon DS (eds). Wiley-Liss: New York, pp. 269-287.
13. Blakesley VA, Kalebic T, Helman LJ, Stannard B, Faria TN, Roberts Jr CT and LeRoith D. (1996). Endocrinology, 137, 410-417.
14. Blum G, Gazit A and Levitzki A. (2000). Biochemistry, 39, 15705-15712.
15. Bohula EA, Salisbury AJ, Sohail M, Playford MP, Riedemann J, Southern EM and Macaulay VM. (2003). J Biol. Chem. 278, 15991-15997.
16. Brazil DP, Park J and Hemmings BA. (2002). Cell, 111, 293-303.
17. Brodt P, Fallavollita L, Khatib AM, Samani AA and Zhang D. (2001). J Biol. Chem., 276, 33608-33615.
18. Brodt P, Samani A and Navab R. (2000). Biochem. Pharmacol., 60, 1101-1107.
19. Burfeind P, Chernicky CL, Rininsland F and Ilan J. (1996). Proc. Natl. Acad. Sci. USA, 93, 7263-7268.
20. Burgaud JL, Resnicoff M and Baserga R. (1995). Biochem. Biophys. Res. Commun., 214, 475-481.
21. Butler AA, Blakesley VA, Poulaki V, Tsokos M, Wood TL and LeRoith D. (1998). Cancer Res., 58, 3021-3027.
22. Chernicky CL, Yi L, Tan H, Gan SU and Ilan J. (2000). Cancer Gene Ther., 7, 384-395.
23. Coppola D, Saunders B, Fu L, Mao W and Nicosia SV. (1999). Cancer Res., 59, 3264-3270.
24. D'Ambrosio C, Ferber A, Resnicoff M and Baserga R. (1996). Cancer Res., 56, 4013-4020.
25. De Leon DD, Wilson DM, Powers M and Rosenfeld RG. (1992). Growth Factors, 6, 327-336.
26. De Meyts P and Whittaker J. (2002). Nat. Rev. Drug Discov., 1, 769-783.
27. Djavan B, Waldert M, Seitz C and Marberger M. (2001). World J. Urol., 19, 225-233.
28. Doerr M and Jones J. (1996). J. Biol. Chem., 271, 2443-2447.
29. Druckmann R and Rohr UD. (2002). Maturitas, 41 (Suppl. 1), S65-S83.
30. Druker BJ. (2002). Eur. J. Cancer, 38 (Suppl. 5), S70-S76.
31. Dunn SE, Ehrlich M, Sharp NJH, Reiss K, Solomon G, Hawkins R, Baserga R and Barrett JC. (1998). Cancer Res., 58, 3353-3361.
32. Dunn SE, Kari FW, French J, Leininger JR, Travlos G, Wilson R and Barrett JC. (1997). Cancer Res., 57, 4667-4672.
33. Dunn SE, Torres JV, Oh JS, Cykert DM and Barrett JC. (2001). Cancer Res., 61, 1367-1374.
34. Favelyukis S, Till JH. Hubbard SR and Miller WT. (2001). Nat. Struct. Biol., 8, 1058-1063.
35. Fry DW. (2003). Exp. Cell Res., 284, 131-139.
36. Giovannucci E. (2001). J. Nutr., 131 (Suppl), 3109S-3120S.
37. Guo N, Ye JJ, Liang SJ, Mineo R, Li SL, Giannini S, Plymate SR, Sikes RA and Fujita-Yamaguchi Y. (2003). Growth Horm. IGF Res., 13, 44-53.
38. Guvakova M and Surmacz E. (1999). Exp. Cell Res., 251, 244-255.
39. Hailey J, Maxwell E, Koukouras K, Bishop WR, Pachter JA and Wang Y. (2002). Mol. Cancer Ther., 1, 1349-1353.
40. Harries M and Smith I. (2002). Endocr. Relat. Cancer. 9, 75-85.
41. Hernandez-Boluda JC and Cervantes F. (2002). Drugs Today, 38, 601-613.
42. Hill MM and Hemmings BA. (2002). Pharmacol. Ther., 93, 243-251.
43. Holbro T, Civenni G and Hynes NE. (2003). Exp. Cell Res., 284, 99-110.
44. Hongo A, D'Ambrosio C, Miura M, Morrione A and Baserga R. (1996). Oncogene, 12, 1231-1238.
45. Hongo A, Yumet G, Resnicoff M, Romano G, O' Connor R and Baserga R. (1998). Cancer Res., 58, 2477-2484.
46. Jacobs S, Cook S, Svoboda ME and Van Wyk JJ. (1986). Endocrinology, 118, 223-226.
47. Kalebic T, Blakesley V, Slade C, Plasschaert S, LeRoith D and Helman LJ. (1998). Int. J. Cancer, 76, 223-227.
48. Kalebic T, Tsokos M and Helman LJ. (1994). Cancer Res., 54, 5531-5534.
49. Kaleko M, Rutter WJ and Miller AD. (1990). Mol. Cell. Biol., 10, 464-473.
50. Kato H, Faria TN, Stannard B, Roberts Jr CT and LeRoith D. (1993). J. Biol. Chem., 268, 2655-2661.
51. Korc M. (1998). Surg. Oncol. Clin. N. Am., 7, 25-41.
52. Lee CT, Park KH, Adachi Y, Seol JY, Yoo CG, Kim YW, Han SK, Shim YS, Coffee K, Dikov MM and Carbone DP. (2003). Cancer Gene Ther., 10, 57-63.
53. Lee CT, Wu S, Gabrilovich D, Chen H, Nadaf-Rahrov S, Ciernik IF and Carbone DP. (1996). Cancer Res., 56, 3038-3041.
54. Levitzki A. (2002). Eur. J. Cancer, 38 (Suppl. 5), S11-S8.
55. Li SL, Kato J, Paz IB, Kasuya J and Fujita-Yamaguchi Y. (1993). Biochem. Biophys. Res. Commun., 196, 92-98.
56. Li SL, Liang SJ, Guo N, Wu AM and Fujita-Yamaguchi Y. (2000). Cancer Immunol. Immunother., 49, 243-252.
57. Liu Y, Lehar S, Corvi C, Payne G and O'Connor R. (1998). Cancer Res., 58, 570-576.
58. Long L, Navab R and Brodt P. (1998). Cancer Res., 58, 3243-3247.
59. Lu Y, Zi X, Zhao Y, Mascarenhas D and Pollak M. (2001). J. Natl. Cancer Inst., 93, 1852-1857.
60. Macaulay VM, Salisbury AJ, Bohula EA, Playford MP, Smorodinsky NI and Shiloh Y. (2001). Oncogene, 20, 4029-4040.
61. Mauro L, Salerno M, Morelli C, Boterberg T, Bracke ME and Surmacz E. (2003). J. Cell Physiol., 194, 108-116.
62. Mauro L, Sisci D, Salerno M, Kim J, Tam T, Guvakova M, Ando S and Surmacz E. (1999). Exp. Cell Res., 252, 439-448.
63. Mendelsohn J and Baselga J. (2000). Oncogene, 19, 6550-6565.
64. Mira E, Manes S, Lacalle RA, Marques G and Martinez-AC. (1999). Endocrinology, 140, 1657-1664.
65. Muller M, Dietel M, Turzynski A and Wiechen K. (1998). Int. J. Cancer, 17, 567-571.
66. Nakamura K, Hongo A, Kodama J, Miyagi Y, Yoshinouchi M and Kudo T. (2000). Cancer Res., 60, 760-765.
67. Navab R, Chevet E, Authier F, Di Guglielmo GM, Bergeron JJ and Brodt P. (2001). J. Biol. Chem., 276, 13644-13649.
68. Neuenschwander S, Roberts Jr CT and LeRoith D. (1995). Endocrinology, 136, 4298-4303.
69. Nicholson KM and Anderson N. (2002). Cell Signal., 14, 381-395.
70. O'Connor R. (1998). Adv. Bioch. Engin/Biotech Scheper T (ed), Vol. 62. Springer-Verlag: Berlin, pp. 138-166.
71. O'Connor R, Fennelly C and Krause D. (2000). Biochem. Soc. Trans., 28, 47-51.
72. O'Connor R, Kauffmann-Zeh A, Liu Y, Lehar S, Evan GI, Baserga R and Blattler WA. (1997). Mol. Cell. Biol., 17, 427-435.
73. Pautsch A, Zoephel A, Ahorn H, Spevak W, Hauptmann R and Nar H. (2001). Structure, 9, 955-965.
74. Pavelic J, Pavelic L, Karadza J, Krizanac S, Unesic J, Spaventi S and Pavelic K. (2002). Mol. Med., 8, 149-157.
75. Peruzzi F, Prisco M, Dews M, Salomoni P, Grassilli E, Romano G, Calabretta B and Baserga R. (1999). Mol. Cell. Biol., 19, 7203-7215.
76. Pietrzkowski Z, Lammers R, Carpenter G, Soderquist AM, Limardo M, Phillips PD, Ullrich A and Baserga R. (1992a). Cell Growth Differ., 3, 199-205.
77. Pietrzkowski Z, Mulholland G, Gomella L, Jameson BA, Wernicke D and Baserga R. (1993). Cancer Res., 53, 1102-1106.
78. Pietrzkowski Z, Wernicke D, Porcu P, Jameson BA and Baserga R. (1992b). Cancer Res., 52, 6447-6451.
79. Pollak M. (2000). Eur. J. Cancer, 36, 1224-1228.
80. Prager D, Li HL, Asa S and Melmed S. (1994). Proc. Natl. Acad. Sci. USA, 91, 2181-2185.
81. Reiss K, D'Ambrosio C, Tu X, Tu C and Baserga R. (1998). Clin. Cancer Res., 4, 2647-2655.
82. Reiss K, Wang JY, Romano G, Tu X, Peruzzi F and Baserga R. (2001a). Oncogene, 20, 490-500.
83. Reiss K, Tu X, Romano G, Peruzzi F, Wang JY and Baserga R. (2001b). Clin. Cancer Res., 7, 2134-2144.
84. Resnicoff M, Abraham D, Yutanawiboonchai W, Rotman HL, Kajstura J, Rubin R, Zoltick P and Baserga R. (1995b). Cancer Res., 55, 2463-2469.
85. Resnicoff M, Burgaud JL, Rotman HL, Abraham D and Baserga R. (1995a). Cancer Res., 55, 3739-3741.
86. Resnicoff M, Sell C, Rubini M, Coppola D, Ambrose D, Baserga R and Rubin R. (1994). Cancer Res., 54, 2218-2222.
87. Rininsland F, Johnson TR, Chernicky CL, Schulze E, Burfeind P and Ilan J. (1997). Proc. Natl. Acad. Sci. USA, 94, 5854-5859.
88. Romano G, Frisco M, Zanocco-Marani T, Peruzzi F, Valentinis B and Baserga R. (1999). J. Cell. Biochem., 72, 294-310.
89. Sachdev D, Li SL, Hartell JS, Fujita-Yamaguchi Y, Miller JS and Yee D. (2003). Cancer Res., 63, 627-635.
90. Sachdev D and Yee D. (2001). Endocr. Relat. Cancer, 8, 197-209.
91. Scharf JG, Dombrowski F and Ramadori G. (2001). Mol. Pathol., 54, 138-144.
92. Scotlandi K, Avnet S, Benini S, Manara MC, Serra M, Cerisano V, Perdichizzi S, Lollini PL, De Giovanni C, Landuzzi L and Picci P. (2002). Int. J. Cancer, 101, 11-16.
93. Scotlandi K, Benini S, Nanni P, Lollini PL, Nicoletti G, Landuzzi L, Serra M, Manara MC, Picci P and Baldini N. (1998). Cancer Res., 58, 4127-4131.
94. Seely BL, Samimi G and Webster NJ. (2002). BMC Cancer, 2, 15-25.
95. Shapiro DN, Jones BG, Shapiro LH, Dias P and Houghton PJ. (1994). J. Clin. Invest., 94, 1235-1242.
96. Shaw LM. (2001). Mol. Cell. Biol., 21, 5082-5093.
97. citsname > Shawver LK, Slamon D and Ullrich A. (2002). Cancer Cell, 1, 117-123.
98. Shepherd PR, Withers D and Siddle K. (1998). Biochem. J., 333, 471-490.
99. Surmacz E. (2000). J. Mammary Gland Biol. Neopl., 5, 95-105.
100. Surmacz E, Sell C, Swantek J, Kato H, Roberts Jr. CT, LeRoith D and Baserga R. (1995). Exp. Cell Res., 218, 370-380.
101. Trojan LA, Kopinski P, Wei MX, Ly A, Glogowska A, Czarny J, Shevelev A, Przewlocki R, Henin D and Trojan J. (2002). Acta Biochim. Pol., 49, 979-990.
102. Ullrich A, Gray A, Tarn AW, Yang-Feng T, Tsubokawa M, Collins C, Henzel W, Le Bon T, Kathuria S, Chen E, Jacobs S, Francke U, Ramachandran J and Fujita-Yamaguchi Y. (1986). EMBO J., 5, 2503-2512.
103. Vuori K and Ruoslahti E. (1994). Science, 266, 1576-1576.
104. White MF. (1998). Mol. Cell. Biochem., 182, 3-11.
105. White MF. (2002). Am. J. Physiol. Endocrinol. Metab., 283, E413-422.
106. Yee D. (2002). Semin. Oncol., 29 (Suppl 11), 86-95.
107. Zhang D and Brodt P. (2003). Oncogene, 22, 974-982.
108. Zia F, Jacobs S, Kull Jr F, Cuttitta F, Mulshine JL and Moody TW. (1996). J. Cell. Biochem. Suppl., 24, 269-275.
109. Zong CS, Chan J, Levy DE, Horvath C, Sadowski HB and Wang LH. (2000). J. Biol Chem., 275, 15099-15105.
110. Zong CS, Zeng L, Jiang Y, Sadowski HB and Wang LH. (1998). J. Biol. Chem., 273, 28065-22872.